Why the study?
Wenxin Keli is clinically used for arrhythmias by acting on multiple ion channel targets, but its effects on the slow delayed rectifier potassium current (IKs) and its potential role in arrhythmogenesis in the aging heart remain largely unknown.
Population
Aged guinea pig hearts and HEK 293B cells stably expressing human KCNQ1/KCNE1 genes
Comparison
Chronic Wenxin Keli treatment across doses and times, with or without Brefeldin A, Dynasore, or HMR1556
Design
In vivo and in vitro experimental study
Answers are grounded in this paper and cite their sources.
Should not change arrhythmia management; leaves open translation of Wenxin Keli effects on potassium currents to human aging hearts.
Background Wenxin Keli (WXKL) is a Chinese patent medicine clinically used for arrhythmias, acting on multiple ion channel targets. However, its effects on the slow delayed rectifier potassium current ( I Ks ) and its potential role in arrhythmogenesis in the aging heart remain largely unknown. Objective To investigate the chronic regulatory effects of WXKL on I Ks and its impact on susceptibility to ventricular arrhythmias in aged hearts. Methods Experiments were performed in aged guinea pig hearts ( in vivo, in vitro ) and in human embryonic kidney (HEK) 293B cells stably expressing human KCNQ1 / KCNE1 genes. I Ks was recorded using whole-cell patch-clamp, and cardiac electrical activity was monitored via lead II electrocardiogram. Ventricular arrhythmias were induced by acute isoproterenol stimulation. Results Chronic WXKL treatment significantly shortened the heart rate–corrected QT interval, suggesting enhanced repolarization capacity in aged guinea pig hearts. Correspondingly, I Ks currents in isolated ventricular myocytes increased in a dose-dependent manner with WXKL administration. In HEK293B– I Ks cells, WXKL time-dependently augmented I Ks . Brefeldin A (forward trafficking inhibitor) alone reduced I Ks , an effect reversed by co-application with WXKL. Dynasore (endocytosis inhibitor) alone increased I Ks , with no additional effect upon WXKL co-application. Moreover, WXKL protected aged hearts from isoproterenol-induced ventricular arrhythmias. However, co-application of HMR1556, an I Ks inhibitor, abolished this protective effect and predisposed the hearts to ventricular tachyarrhythmias. Conclusion Chronic WXKL treatment upregulates I Ks through inhibition of membrane internalization without affecting forward trafficking, thereby reducing susceptibility to ventricular arrhythmogenesis in aging hearts.
No takes yet. Share an insight, caveat, or question.
Zou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: